Zimmer Biomet Q4 Revenue Up 10% to $1.52B, EPS Jump 16%, Raises 2026 Guidance
Zimmer Biomet’s Q4 2025 revenue rose 10% year-over-year to $1.52 billion, driven by a 14% jump in joint reconstruction and 8% growth in spinal device sales. Adjusted EPS climbed 16% to $1.68, and management lifted 2026 revenue guidance to $6.5–$6.7 billion with 6–8% organic growth.
1. Q4 2025 Financial Results
Zimmer Biomet reported Q4 2025 revenue of $1.52 billion, up 10% year-over-year. Adjusted EPS rose 16% to $1.68, reflecting operational leverage and cost-efficiency measures implemented during the prior year.
2. Segment Performance
Joint reconstruction sales climbed 14% as new implant launches gained market share, while spine and trauma products grew 8% on expanded distribution and strong end-market demand. Other segments, including dental and sports medicine, contributed modestly to overall growth.
3. 2026 Guidance and Outlook
Management raised full-year 2026 revenue guidance to $6.5–$6.7 billion, targeting 6–8% organic growth, and expects adjusted EPS of $6.50–$6.70. The company plans further margin expansion through supply-chain optimization and R&D efficiencies.